Squamous Cell Carcinoma of the Anal Canal: Patterns and Predictors of Failure and Implications for Intensity-Modulated Radiation Treatment Planning
Journal Article
·
· International Journal of Radiation Oncology, Biology and Physics
- Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
- Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, IL (United States)
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
- Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
Purpose: Intensity-modulated radiation treatment (IMRT) is increasingly used in the treatment of squamous cell carcinoma of the anal canal (SCCAC). Prevention of locoregional failure (LRF) using IMRT requires appropriate clinical target volume (CTV) definition. To better define the CTV for IMRT, we evaluated patterns and predictors of LRF in SCCAC patients given conventional radiation treatment. Methods and Materials: We reviewed records of 180 SCCAC patients treated with conventional radiation with or without chemotherapy at our institution between January 1990 and March 2007. All patients received radiation; the median primary tumor dose was 45 Gy. A total of 173 patients also received mitomycin-based chemotherapy. Results: Median follow-up was 40 months. Actuarial 3-year colostomy-free survival was 89% and overall survival (OS) 88%. Actuarial 3-year LRF was 23%. A total of 45 patients had LRF, with 35 (78%) occurring locally in the primary site (25 local only, 10 local and regional); however, 20 (44%) had regional components of failure within the pelvis or inguinal nodes (10 regional only, 10 local and regional). Cumulative sites of LRF (patients may have one or more site of failure) were as follows: primary, 35; inguinal, 8; external perianal, 5; common iliac, 4; presacral, 3; distal rectum, 2; external iliac, 2; and internal iliac, 2. All patients with common iliac failure had cT3 or N+ disease. Conclusions: The observed patterns of failure support inclusion of the inguinal and all pelvic nodal groups in the CTV for IMRT. In patients with advanced tumor or nodal stage, common iliac nodes should also be included in the CTV.
- OSTI ID:
- 21438041
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 4 Vol. 78; ISSN IOBPD3; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Intensity-Modulated Radiation Therapy for the Treatment of Squamous Cell Anal Cancer With Para-aortic Nodal Involvement
Bladder Cancer Patterns of Pelvic Failure: Implications for Adjuvant Radiation Therapy
External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer
Journal Article
·
Sun Nov 01 00:00:00 EDT 2009
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21362216
Bladder Cancer Patterns of Pelvic Failure: Implications for Adjuvant Radiation Therapy
Journal Article
·
Thu Jan 31 23:00:00 EST 2013
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:22149759
External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer
Journal Article
·
Wed Mar 15 00:00:00 EDT 2017
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:22649862
Related Subjects
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTI-INFECTIVE AGENTS
ANTIBIOTICS
ANTIMITOTIC DRUGS
ANTINEOPLASTIC DRUGS
BODY
CARCINOMAS
CHEMOTHERAPY
DIGESTIVE SYSTEM
DISEASES
DRUGS
FAILURES
GASTROINTESTINAL TRACT
INTESTINES
LARGE INTESTINE
MEDICINE
MITOMYCIN
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANS
RADIOLOGY
RADIOTHERAPY
RECTUM
THERAPY
ANTI-INFECTIVE AGENTS
ANTIBIOTICS
ANTIMITOTIC DRUGS
ANTINEOPLASTIC DRUGS
BODY
CARCINOMAS
CHEMOTHERAPY
DIGESTIVE SYSTEM
DISEASES
DRUGS
FAILURES
GASTROINTESTINAL TRACT
INTESTINES
LARGE INTESTINE
MEDICINE
MITOMYCIN
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANS
RADIOLOGY
RADIOTHERAPY
RECTUM
THERAPY